A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins
On Tuesday, Merck reported better-than-expected first-quarter profits, driven by a huge jump in sales of its cancer drug, Keytruda.
The company posted a sales increase of 10.6% in the second quarter.
The campaign is appearing in millennial- and women-focused outlets such as Refinery29, Instagram, Bravo!, HGTV, and Cosmopolitan.
Caregivers are intimately involved in patient health, and that includes deciding on treatments, a new study suggests.